
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
Manufacturing
about 23 years ago
Quality Controlabout 23 years ago
Overviewabout 23 years ago
Executive Summaryabout 23 years ago
Quality Assuranceabout 23 years ago
Conclusion





